trending Market Intelligence /marketintelligence/en/news-insights/trending/-kUZZdEBxX0rwzqxgCX0Nw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Opko to review phase 3 study on HGH drug due to outliers

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Opko to review phase 3 study on HGH drug due to outliers

Opko Health Inc.'s phase 3 study of its investigational long-acting human growth hormone product, hGH-CTP, in adults with growth hormone deficiency did not achieve its primary endpoint.

The drug failed to show a statistical difference compared to placebo in changing the trunk fat mass from baseline to 26 weeks.

However, after unblinding the study, the company said it has identified one or more outliers that might have affected the primary outcome and plans to undertake a further review of the study population as soon as possible.

Opko has also initiated a phase 3 study in pre-pubertal growth hormone deficient children to evaluate weekly treatment with the drug versus daily injections of Genotropin.

The company has a worldwide collaboration and license agreement with Pfizer Inc. for the development and commercialization of hGH-CTP. Under the agreement, Opko is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.